BMS Reports Results from P-III (MAVA-LTE) Trial of Camzyos to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Shots:
- BMS reported 3.5yrs. data from EXPLORER-LTE cohort of 5yrs. P-III (MAVA-LTE) trial of Camzyos to treat symptomatic oHCM patients who concluded P-III (EXPLORER-HCM; n=251) trial
- 211/231 were on Camyos (185 & 99 reached wk.156 & 180, respectively). Analysis showed a 55.3 mmHg reduced Valsalva LVOT gradient (both wks.156 & 180) with 40.2 mmHg (wk.156) & 40.3 mmHg (wk.180) reduced mean resting LVOT gradient; mean LVEF decreased by 11% (wk.180); median NT-proBNP levels dropped by 504 ng/L (wk.156) & 562 ng/L (wk.180)
- Reductions in mean left atrial volume index were 3.5 mL/m² (wks.144) & 5.5 mL/m² (wks.180). CR was observed in 46.8% of patients at wk.180 (66.3% were NYHA class I), with sustained improvement in shortness of breath at wks.156 & 180
Ref: BMS | Image: BMS
Related News:- BMS’ Camzyos (mavacamten) Receives NICE Recommendation for adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
